Santen Pharmaceutical Co., Ltd. (TYO:4536)

Santen Pharmaceutical Ratios and Metrics

Market cap in millions JPY. Fiscal year is April - March.

Total Valuation

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jul 29, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Market Capitalization	649,969	574,345	484,047	559,190	424,342	490,898
Market Cap Growth	16.94%	18.66%	-13.44%	31.78%	-13.56%	-19.37%
Enterprise Value	602,874	511,855	405,379	476,424	362,459	422,435
Last Close Price	2020.50	1785.50	1386.62	1469.04	1056.18	1112.09

Price Ratios

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jul 29, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
PE Ratio	17.75	15.37	13.35	21.00	-	18.04
Forward PE	16.51	16.06	14.12	17.09	25.03	16.26
PS Ratio	2.23	1.97	1.61	1.85	1.52	1.84
PB Ratio	2.20	1.94	1.70	1.83	1.45	1.46
P/TBV Ratio	2.88	2.55	2.30	2.52	2.15	2.37
P/FCF Ratio	17.73	15.67	8.92	8.83	21.36	17.11
P/OCF Ratio	14.94	13.20	7.95	7.70	11.42	10.66
PEG Ratio	3.58	2.17	1.34	0.56	2.79	2.79

EV Ratios

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jul 29, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
EV/Sales Ratio	2.07	1.76	1.35	1.58	1.30	1.59
EV/EBITDA Ratio	9.34	7.93	6.12	6.77	6.90	7.98
EV/EBIT Ratio	13.04	11.07	8.39	9.13	10.27	11.78
EV/FCF Ratio	16.45	13.96	7.47	7.52	18.24	14.72

Financial Efficiency

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jul 29, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Debt / Equity Ratio	0.12	0.12	0.12	0.11	0.12	0.10
Debt / EBITDA Ratio	0.54	0.54	0.52	0.49	0.69	0.62
Debt / FCF Ratio	0.95	0.95	0.63	0.55	1.82	1.15
Net Debt / Equity Ratio	-0.16	-0.16	-0.21	-0.20	-0.07	-0.15
Net Debt / EBITDA Ratio	-0.71	-0.71	-0.89	-0.85	-0.41	-0.95
Net Debt / FCF Ratio	-1.26	-1.26	-1.08	-0.95	-1.09	-1.74
Asset Turnover	0.70	0.70	0.71	0.71	0.63	0.62
Inventory Turnover	2.10	2.10	2.72	2.99	2.95	2.79
Quick Ratio	1.74	1.74	1.90	2.00	1.85	1.91
Current Ratio	2.60	2.60	2.58	2.55	2.38	2.39
Return on Equity (ROE)	12.93%	12.93%	12.14%	8.92%	-4.75%	8.45%
Return on Assets (ROA)	6.94%	6.94%	7.14%	7.61%	5.01%	5.20%
Return on Invested Capital (ROIC)	15.55%	15.37%	15.46%	18.05%	12.64%	10.12%
Return on Capital Employed (ROCE)	13.80%	13.80%	15.00%	15.20%	10.60%	9.90%

Yields

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jul 29, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Earnings Yield	5.75%	6.51%	7.49%	4.76%	-3.52%	5.54%
FCF Yield	5.64%	6.38%	11.21%	11.33%	4.68%	5.85%
Dividend Yield	2.14%	2.13%	2.60%	2.25%	3.03%	2.88%
Payout Ratio	33.83%	33.83%	33.40%	44.59%	-	44.07%
Buyback Yield / Dilution	6.10%	6.10%	5.01%	4.98%	3.26%	-0.02%
Total Shareholder Return	8.24%	8.22%	7.61%	7.22%	6.29%	2.86%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 29, 2026

Data Sources Report a data error